TOKYO -- U.S. regulators' approval on Monday of aducanumab, an Alzheimer's treatment jointly developed by Massachusetts-based Biogen and Tokyo-based Eisai, is potentially a life-changing moment for millions.
This is the first time that the U.S. Food and Drug Administration has approved a drug designed to slow the progress of Alzheimer's in sufferers. Previous drugs targeting the disease have aimed only to alleviate symptoms.
